279 related articles for article (PubMed ID: 37490255)
1. Targeting miRNA and using miRNA as potential therapeutic options to bypass resistance in pancreatic ductal adenocarcinoma.
Vahabi M; Dehni B; Antomás I; Giovannetti E; Peters GJ
Cancer Metastasis Rev; 2023 Sep; 42(3):725-740. PubMed ID: 37490255
[TBL] [Abstract][Full Text] [Related]
2. Leptin-elicited miRNA-342-3p potentiates gemcitabine resistance in pancreatic ductal adenocarcinoma.
Ma L; Fan Z; Du G; Wang H
Biochem Biophys Res Commun; 2019 Feb; 509(3):845-853. PubMed ID: 30638935
[TBL] [Abstract][Full Text] [Related]
3. MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic targets?
Brunetti O; Russo A; Scarpa A; Santini D; Reni M; Bittoni A; Azzariti A; Aprile G; Delcuratolo S; Signorile M; Gnoni A; Palermo L; Lorusso V; Cascinu S; Silvestris N
Oncotarget; 2015 Sep; 6(27):23323-41. PubMed ID: 26259238
[TBL] [Abstract][Full Text] [Related]
4. Identification of candidate miRNA biomarkers for pancreatic ductal adenocarcinoma by weighted gene co-expression network analysis.
Giulietti M; Occhipinti G; Principato G; Piva F
Cell Oncol (Dordr); 2017 Apr; 40(2):181-192. PubMed ID: 28205147
[TBL] [Abstract][Full Text] [Related]
5. miRNA-181b increases the sensitivity of pancreatic ductal adenocarcinoma cells to gemcitabine in vitro and in nude mice by targeting BCL-2.
Cai B; An Y; Lv N; Chen J; Tu M; Sun J; Wu P; Wei J; Jiang K; Miao Y
Oncol Rep; 2013 May; 29(5):1769-76. PubMed ID: 23440261
[TBL] [Abstract][Full Text] [Related]
6. Dysregulation of miRNAs Targeting the IGF-1R Pathway in Pancreatic Ductal Adenocarcinoma.
Dobre M; Herlea V; Vlăduţ C; Ciocîrlan M; Balaban VD; Constantinescu G; Diculescu M; Milanesi E
Cells; 2021 Jul; 10(8):. PubMed ID: 34440625
[TBL] [Abstract][Full Text] [Related]
7. MiRNA-3662 reverses the gemcitabine resistance in pancreatic cancer through regulating the tumor metabolism.
Liu A; Zhou Y; Zhao T; Tang X; Zhou B; Xu J
Cancer Chemother Pharmacol; 2021 Aug; 88(2):343-357. PubMed ID: 33993382
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-155 Controls Exosome Synthesis and Promotes Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma.
Mikamori M; Yamada D; Eguchi H; Hasegawa S; Kishimoto T; Tomimaru Y; Asaoka T; Noda T; Wada H; Kawamoto K; Gotoh K; Takeda Y; Tanemura M; Mori M; Doki Y
Sci Rep; 2017 Feb; 7():42339. PubMed ID: 28198398
[TBL] [Abstract][Full Text] [Related]
9. Molecular mechanisms underlying the role of microRNAs in the chemoresistance of pancreatic cancer.
Garajová I; Le Large TY; Frampton AE; Rolfo C; Voortman J; Giovannetti E
Biomed Res Int; 2014; 2014():678401. PubMed ID: 25250326
[TBL] [Abstract][Full Text] [Related]
10. The miRacle in Pancreatic Cancer by miRNAs: Tiny Angels or Devils in Disease Progression.
Hawa Z; Haque I; Ghosh A; Banerjee S; Harris L; Banerjee SK
Int J Mol Sci; 2016 May; 17(6):. PubMed ID: 27240340
[TBL] [Abstract][Full Text] [Related]
11. Clinical potential of microRNAs in pancreatic ductal adenocarcinoma.
Steele CW; Oien KA; McKay CJ; Jamieson NB
Pancreas; 2011 Nov; 40(8):1165-71. PubMed ID: 22001830
[TBL] [Abstract][Full Text] [Related]
12. Circulating microRNAs as Potential Diagnostic, Prognostic and Therapeutic Targets in Pancreatic Cancer.
Ebrahimi S; Hosseini M; Ghasemi F; Shahidsales S; Maftouh M; Akbarzade H; Parizadeh SA; Hassanian SM; Avan A
Curr Pharm Des; 2016; 22(42):6444-6450. PubMed ID: 27539232
[TBL] [Abstract][Full Text] [Related]
13. Global microRNA expression profiling of microdissected tissues identifies miR-135b as a novel biomarker for pancreatic ductal adenocarcinoma.
Munding JB; Adai AT; Maghnouj A; Urbanik A; Zöllner H; Liffers ST; Chromik AM; Uhl W; Szafranska-Schwarzbach AE; Tannapfel A; Hahn SA
Int J Cancer; 2012 Jul; 131(2):E86-95. PubMed ID: 21953293
[TBL] [Abstract][Full Text] [Related]
14. Interrelationship between miRNA and splicing factors in pancreatic ductal adenocarcinoma.
Supadmanaba IGP; Mantini G; Randazzo O; Capula M; Muller IB; Cascioferro S; Diana P; Peters GJ; Giovannetti E
Epigenetics; 2022 Apr; 17(4):381-404. PubMed ID: 34057028
[TBL] [Abstract][Full Text] [Related]
15. miR-125a-3p is responsible for chemosensitivity in PDAC by inhibiting epithelial-mesenchymal transition via Fyn.
Liu G; Ji L; Ke M; Ou Z; Tang N; Li Y
Biomed Pharmacother; 2018 Oct; 106():523-531. PubMed ID: 29990840
[TBL] [Abstract][Full Text] [Related]
16. MiR-10b inhibits migration and invasion of pancreatic ductal adenocarcinoma via regulating E2F7.
Xu C; Qi X
J Clin Lab Anal; 2020 Oct; 34(10):e23442. PubMed ID: 32592206
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA Profiling Implies New Markers of Gemcitabine Chemoresistance in Mutant p53 Pancreatic Ductal Adenocarcinoma.
Dhayat SA; Mardin WA; Seggewiß J; Ströse AJ; Matuszcak C; Hummel R; Senninger N; Mees ST; Haier J
PLoS One; 2015; 10(11):e0143755. PubMed ID: 26606261
[TBL] [Abstract][Full Text] [Related]
18. Analysis of Blood Plasma MicroRNAs to Enable Identification of Patients with Pancreatic Ductal Adenocarcinoma Who Will Benefit from Surgical Resection.
Gablo N. A; Procházka V; Hlavsa J; Kiss I; Srovnal J; Kala Z; Slabý O
Klin Onkol; 2019; 32(Suppl 1):174-176. PubMed ID: 31064193
[TBL] [Abstract][Full Text] [Related]
19. Identification of Serum miRNA Signature and Establishment of a Nomogram for Risk Stratification in Patients With Pancreatic Ductal Adenocarcinoma.
Kandimalla R; Shimura T; Mallik S; Sonohara F; Tsai S; Evans DB; Kim SC; Baba H; Kodera Y; Von Hoff D; Chen X; Goel A
Ann Surg; 2022 Jan; 275(1):e229-e237. PubMed ID: 32398486
[TBL] [Abstract][Full Text] [Related]
20. Circular RNA circ-MTHFD1L induces HR repair to promote gemcitabine resistance via the miR-615-3p/RPN6 axis in pancreatic ductal adenocarcinoma.
Chen ZW; Hu JF; Wang ZW; Liao CY; Kang FP; Lin CF; Huang Y; Huang L; Tian YF; Chen S
J Exp Clin Cancer Res; 2022 Apr; 41(1):153. PubMed ID: 35459186
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
